Silexion Therapeutics Corp. (SLXN) has announced a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025.
Trading on a split-adjusted basis will begin on July 29 under the same Nasdaq ticker "SLXN," with a new CUSIP number assigned to the post-split shares.
As part of the reverse split, every fifteen existing ordinary shares will automatically combine into one, increasing the par value from $0.0009 to $0.0135 per share. No fractional shares will be issued; shareholders entitled to a fraction will receive one whole share. Adjustments for shareholders will occur automatically, whether shares are held directly or via a broker.
Chairman and CEO Ilan Hadar said the reverse split underscores Silexion's commitment to maintaining its Nasdaq listing, improving capital market positioning, and supporting its long-term growth strategy. He emphasized the move follows preclinical progress with RNAi candidate SIL-204 and expanded efforts targeting KRAS-driven cancers.
The reverse split aims to bring the company's stock price into compliance with Nasdaq's minimum bid requirement under Rule 5550(a)(2), facilitating continued access to equity markets and supporting the company's broader strategic and financing initiatives.
Wednesday, SLXN closed at $0.695, down 10.40%, and edged slightly lower in after-hours trading to $0.69, a 0.72% decline on the NasdaqGM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.